Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Cash & Equivalents (2019 - 2026)

Enliven Therapeutics has reported Cash & Equivalents over the past 8 years, most recently at $132.2 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $132.2 million for Q1 2026, up 29.97% from a year ago — trailing twelve months through Mar 2026 was $132.2 million (up 29.97% YoY), and the annual figure for FY2025 was $98.9 million, down 20.32%.
  • Cash & Equivalents reached $132.2 million in Q1 2026 per ELVN's latest filing, up from $98.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $292.1 million in Q1 2023 and bottomed at $73.8 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $100.6 million (2024), compared with a mean of $115.9 million.
  • The largest annual shift saw Cash & Equivalents surged 192.46% in 2023 before it plummeted 48.93% in 2024.
  • Over 5 years, Cash & Equivalents stood at $75.5 million in 2022, then soared by 32.57% to $100.1 million in 2023, then grew by 23.94% to $124.1 million in 2024, then decreased by 20.32% to $98.9 million in 2025, then surged by 33.66% to $132.2 million in 2026.
  • Business Quant data shows Cash & Equivalents for ELVN at $132.2 million in Q1 2026, $98.9 million in Q4 2025, and $101.7 million in Q3 2025.